Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (ACET) is a clinical-stage biotechnology company pioneering allogeneic gamma delta T cell therapies for cancer treatment. This page serves as the definitive source for verified corporate developments, research milestones, and strategic updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapy pipeline advancements, financial disclosures, and scientific collaborations, with particular focus on the company's CAR/TCR engineering platform and TCR-like antibody research.
Key content categories include updates on lead candidate ADI-001 for B-cell malignancies, preclinical developments for solid tumor targets like CD70, and strategic initiatives such as the Regeneron Pharmaceuticals collaboration. All materials are vetted for accuracy and relevance to investment analysis.
Bookmark this page for streamlined access to essential updates about Adicet Bio's innovative approach to universal cell therapies. Check regularly for new developments in their mission to advance off-the-shelf immunotherapies for oncology applications.
Adicet Bio expanded its ADI-001 Phase 1 clinical trial to include six autoimmune disease indications, with preliminary lupus nephritis data expected in 1H25. The company reported Q3 2024 financial results with a net loss of $30.5 million ($0.34 per share). R&D expenses were $26.3 million, while G&A expenses reached $6.9 million. The company maintains a strong financial position with $202.1 million in cash and equivalents, expected to fund operations into 2H26. FDA granted Fast Track Designation for ADI-270 in metastatic/advanced clear cell renal cell carcinoma.
Adicet Bio (NASDAQ: ACET) has announced its upcoming participation at the American College of Rheumatology (ACR) Convergence 2024 meeting in Washington, D.C., scheduled for November 14-19, 2024. The company will deliver an oral presentation about ADI-001, their allogeneic CD20-targeted γδ CAR T cell therapy, which shows potential for improved tissue homing in autoimmune indications. The presentation, titled under abstract number 1866169, will be delivered by Dr. Monica Moreno on November 19, 2024, at 12:00 p.m. ET during the Miscellaneous Rheumatic & Inflammatory Diseases II session.
Adicet Bio (ACET), a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies, announces its participation in three major investor conferences in November 2024. The company will attend the Truist Securities BioPharma Symposium in New York for 1x1 meetings, the Guggenheim Securities Healthcare Innovation Conference in Boston featuring a fireside chat, and the Jefferies London Healthcare Conference. CEO Chen Schor will lead fireside discussions at both the Guggenheim and Jefferies events. Live webcasts will be available on Adicet's website with 30-day replay access.
Adicet Bio (Nasdaq: ACET) announced inducement grants to three new employees hired in October 2024. The company granted non-qualified stock options to purchase 59,800 shares at an exercise price of $1.28 per share. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years. These awards were granted under Adicet's 2022 Inducement Plan, approved by the compensation committee as material inducement for employment in accordance with Nasdaq Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) announced FDA clearance of an IND amendment to evaluate ADI-001 in idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) as part of its ongoing Phase 1 trial in autoimmune diseases. This expands ADI-001's clinical development program to six autoimmune diseases. Patient enrollment for the IIM and SPS cohort is expected to begin in Q1 2025.
The company plans to report initial clinical data from the Phase 1 study in multiple autoimmune diseases in H1 2025. The ADI-001 Phase 1 program will have four separate arms, enrolling patients with various autoimmune conditions. Enrolled patients will receive a single dose of ADI-001, with primary objectives to evaluate safety and tolerability.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to four new employees hired in September 2024. The awards include non-qualified stock options to purchase a total of 33,600 shares of Adicet's common stock at an exercise price of $1.44 per share.
The vesting schedule for these options is as follows: 25% of the shares will vest on the one-year anniversary of each recipient's start date, with the remaining 75% vesting in 36 monthly installments thereafter. Full vesting will occur on the fourth anniversary of the recipient's start date, subject to continued employment.
These awards were granted outside of Adicet's stockholder-approved equity incentive plans, under the company's 2022 Inducement Plan. The compensation committee authorized the awards as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) announced its upcoming oral presentation at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference. The event is scheduled for October 16-17, 2024, in Philadelphia, PA.
The presentation, titled 'ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications', will be delivered by Shon Green, Ph.D. It is part of the 'Novel Targets and Effector Cells' session and is assigned Abstract Number 8.
The presentation is scheduled for October 17, 2024, from 11:15 a.m. to 11:30 a.m. ET. Adicet Bio, a clinical stage biotechnology company, focuses on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Adicet Bio (Nasdaq: ACET) has opened enrollment for a Phase 1 clinical trial of ADI-001 in autoimmune diseases. The trial will focus on lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). Enrollment is currently open for LN patients, with SLE, SSc, and AAV enrollment expected to begin in Q4 2024.
The FDA has granted Fast Track Designation to ADI-001 for relapsed/refractory class III or IV LN treatment. The Phase 1 study consists of three arms, with patients receiving a single dose of ADI-001. Primary objectives include evaluating safety and tolerability, while secondary objectives focus on cellular kinetics, pharmacodynamics, autoantibody titers, and disease activity scores.
Adicet anticipates reporting preliminary clinical data for all indications in the first half of 2025.
Adicet Bio (Nasdaq: ACET) has announced promising clinical biomarker data for ADI-001 from the Phase 1 GLEAN trial, reinforcing its potential as a best-in-class allogeneic cell therapy for autoimmune diseases. Key findings include:
1. Robust tissue trafficking with high levels of ADI-001 in secondary lymphoid tissue
2. Significant chimeric antigen receptor (CAR) T cell activation
3. Complete CD19+ B cell depletion in secondary lymphoid tissue
The data shows superior exposure of ADI-001 in secondary lymphoid tissue compared to published third-party data for alpha-beta CAR T therapies. Adicet is advancing ADI-001 clinical programs in various autoimmune conditions and expects to report initial clinical data in the first half of 2025.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to three new employees hired in August 2024. The awards include non-qualified stock options to purchase a total of 30,600 shares of Adicet's common stock at an exercise price of $1.46 per share.
The vesting schedule for these options is structured as follows: 25% of the shares will vest on the one-year anniversary of each recipient's start date, with the remaining 75% vesting in 36 monthly installments thereafter. Full vesting will occur on the fourth anniversary of the recipient's start date, subject to continued employment.
These awards were granted outside of Adicet's stockholder-approved equity incentive plans, under the company's 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
